Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7925075 | 0.88 | SLC1A3 (0.33) | GRIK1GRIK2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8847222 | 0.80 | GRIK1 (0.35) | GRIK1GRIK2 | |
| SCHEMBL7555373 | 0.80 | GRIK1 (0.35) | GRIK1GRIK2 | |
| SCHEMBL25135650 | 0.79 | SLC1A3 (0.32) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL8847089 | 0.79 | GRIK1 (0.34) | GRIK1GRIK2 | |
| SCHEMBL8847128 | 0.79 | GRIK1 (0.34) | GRIK1GRIK2 | |
| SCHEMBL8847050 | 0.77 | GRIK1 (0.33) | GRIK1GRIK2 | |
| SCHEMBL8847051 | 0.77 | GRIK1 (0.33) | GRIK1GRIK2 | |
| SCHEMBL7551523 | 0.74 | CYP1A2 (0.42) | — | |
| SCHEMBL5076843 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2533344-B1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, ELECTROCHEMICAL ELEMENT USING THE SAME, AND ALKYNYL COMPOUND USED THEREFOR | UBE INDUSTRIES (JP) | 2016-07-20 | — | — | EP | claimed |
| US-20020013367-A1 | Antiproliferative and neurotrophic molecules | NAU HEINZ (DE) | 2002-01-31 | — | — | US | claimed |
| US-20250233206-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-07-17 | — | — | US | disclosed |
| US-12315883-B2 | Non-aqueous electrolyte solution and non-aqueous electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-05-27 | — | — | US | disclosed |
| EP-4553918-A1 | NEGATIVE ELECTRODE, BATTERY, AND METHOD FOR COVERING BATTERY MATERIAL | DAIKIN INDUSTRIES, LTD. (JP) | 2025-05-14 | — | — | EP | disclosed |
| EP-4553940-A1 | SECONDARY BATTERY | DAIKIN INDUSTRIES, LTD. (JP) | 2025-05-14 | — | — | EP | disclosed |
| EP-4539193-A1 | ELECTROLYTE SOLUTION AND SECONDARY BATTERY USING SAME | DAIKIN INDUSTRIES, LTD. (JP) | 2025-04-16 | — | — | EP | disclosed |
| US-12278336-B2 | Alkali metal electrode treatment agent, electrolytic solution for alkali metal secondary battery, alkali metal electrode, alkali metal secondary battery, and module | DAIKIN INDUSTRIES, LTD. (JP) | 2025-04-15 | — | — | US | disclosed |
| US-20250096327-A1 | ELECTROLYTIC SOLUTION AND SECONDARY BATTERY USING SAME | DAIKIN INDUSTRIES, LTD. (JP) | 2025-03-20 | — | — | US | disclosed |
| EP-4391139-A1 | ELECTROLYTE SOLUTION, ELECTROCHEMICAL DEVICE, SECONDARY BATTERY, AND LITHIUM ION SECONDARY BATTERY | DAIKIN INDUSTRIES, LTD. (JP) | 2024-06-26 | — | — | EP | disclosed |
| US-12015121-B2 | Electrolyte, electrochemical device, lithium ion secondary battery, and module | DAIKIN INDUSTRIES, LTD. (JP) | 2024-06-18 | — | — | US | disclosed |
| US-20150364794-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-12-17 | — | — | US | disclosed |
| EP-2883867-A2 | Non-aqueous electrolytic solution, electrochemical element using the same and alkynyl compound used therefor | Ube Industries, Ltd. (JP) | 2015-06-17 | — | — | EP | disclosed |
| EP-2685540-A1 | NONAQUEOUS ELECTROLYTE AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY USING SAME | Mitsubishi Chemical Corporation (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-20130330609-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-12-12 | — | — | US | disclosed |
| EP-2672561-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY USING SAME | Mitsubishi Chemical Corporation (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-20130316229-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-11-28 | — | — | US | disclosed |
| EP-2533344-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, ELECTROCHEMICAL ELEMENT USING SAME, AND ALKYNYL COMPOUND USED THEREFOR | Ube Industries, Ltd. (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-20120301797-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, ELECTROCHEMICAL ELEMENT USING SAME, AND ALKYNYL COMPOUND USED THEREFOR | UBE INDUSTRIES, LTD. (JP) | 2012-11-29 | — | — | US | disclosed |
| WO-2001002423-A9 | 2'-GUANIDINYL-SUBSTITUTED OLIGONUCLEOTIDES AND GENE EXPRESSION MODULATION THEREWITH | ISIS PHARMACEUTICALS INC (US) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013367-A1 | Antiproliferative and neurotrophic molecules | BDNF, NGF, NTRK2 | GRIK1 305/4885GRIK2 229/4885SLC1A3 163/4885 |
| US-20120301797-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION, ELECTROCHEMICAL ELEMENT USING SAME, AND ALKYNYL COMPOUND USED THEREFOR | WEE2, WEE1, NOTUM | GRIK1 1655/4885GRIK2 1967/4885SLC1A3 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.